Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure

Thomas Mondritzki1,2*, Thuy Anh Mai2, Julia Vogel2,3, Elisabeth Pook1, Pierre Wasnaire1, Carsten Schmeck1, Jörg Hüser1, Wilfried Dinh1,2,4, Hubert Truebel1,2, and Peter Kolkhof1

1Bayer AG, Wuppertal, Germany; 2University of Witten/Herdecke, Witten, Germany; 3University of Duisburg-Essen, Essen, Germany; and 4Department of Cardiology, HELIOS Clinic Wuppertal, University Hospital Witten/Herdecke, Wuppertal, Germany

Received 11 May 2020; revised 8 September 2020; accepted 9 September 2020; online publish-ahead-of-print 9 October 2020

Aims Arginine vasopressin (AVP) mediates deleterious effects via vascular V1a and renal V2 receptors in heart failure (HF). Despite positive short-term decongestive effects in phase II HF studies, selective V2 receptor antagonism has shown no long-term mortality benefit, potentially related to unopposed V1a receptor activation. We compared the novel dual V1a/V2 receptor antagonist pecavaptan with the selective V2 receptor antagonist tolvaptan in pre-clinical HF models.

Methods and results In vitro IC50 determination in recombinant cell lines revealed similar receptor selectivity profiles (V2:V1a) of tolvaptan and pecavaptan for human and dog AVP receptors, respectively. Two canine models were used to compare haemodynamic and aquaretic effects: (i) anaesthetised dogs with tachypacing-induced HF, and (ii) conscious telemetric dogs with a non-invasive cardiac output (CO) monitor. Tolvaptan and pecavaptan exhibited no differences in urinary output. In HF dogs, pecavaptan counteracted the AVP-induced increase in afterload and decrease in CO (pecavaptan: 1.83 ± 0.31 L/min; vs. tolvaptan: 1.46 ± 0.07 L/min, P < 0.05). In conscious telemetric animals, pecavaptan led to a significant increase in CO (+0.26 ± 0.17 L/min, P = 0.0086 vs. placebo), in cardiac index (+0.58 ± 0.39 L/min/m², P = 0.009 vs. placebo) and a significant decrease in total peripheral resistance (−5348.6 ± 3601.3 dyn x s/cm², P < 0.0001 vs. placebo), whereas tolvaptan was without any significant effect.

Conclusions Simultaneous blockade of vascular V1a and renal V2 receptors efficiently induces aquaresis and counteracts AVP-mediated haemodynamic aggravation in HF models. Dual V1a/V2 antagonism may lead to improved outcomes in HF.

Keywords Animal model • Heart failure • Pecavaptan • Vasopressin antagonist • V1a receptor • V2 receptor

Introduction Most hospitalisations for acute heart failure (HF) are due to signs and symptoms of congestion and fluid overload. Once patients are hospitalised for HF exacerbation, mortality and re-admission rates are very high in the subsequent 60–90 days (up to 15% and 30%, respectively). Loop diuretics are the main treatment for patients with acute HF but are associated with neurohormonal stimulation and worsening renal function, and they do not improve long-term outcomes. Therefore, adequate management of congestion while

© 2020 Bayer AG. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article published under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
offering renal protection remains a relevant target in the treatment of HF. Antagonists to arginine vasopressin (AVP) may provide an alternative decongestive strategy.

Arginine vasopressin acts via three different receptors: the V1a, V1b and V2 receptors. The vasopressin V2 receptor is located in the renal collecting duct, and binding of AVP mediates antidiuresis via the aquaporin-2 system and blockade of the V2 receptor causes free water excretion (aquareisis).4–6 Tolvaptan, a selective V2 receptor antagonist given as adjunctive therapy to loop diuretics, produced a significant decongestive effect without worsening renal function while patients were hospitalised for HF. However, there was no benefit of tolvaptan on mortality or morbidity in the long-term phase of the EVEREST phase III acute HF trial.7,8 Given the selective V2 receptor blockade by tolvaptan, a compensatory increase in plasma AVP levels has been hypothesised to result in enhanced agonism at the vascular smooth muscle cell V1a receptor, with potentially adverse myocardial, renal and vascular effects.9 Thus, these unfavourable effects mediated by V1a receptor activation may have offset any favourable effects of renal protective decongestion by blocking the V2 receptor.

Recently, pecavaptan (BAY 1753011) was discovered as a novel, dual-acting V1a/V2 receptor antagonist with oral bioavailability.10 Pecavaptan has almost identical affinities (Kᵢ values) of 0.5 and 0.6 nM for the human V1a and V2 receptor, respectively, and thus a 1:1 receptor profile in vitro. We aimed to investigate the canine AVP receptor selectivity profile of pecavaptan in vivo before initiating in vivo studies in different pre-clinical dog models. We subsequently investigated whether dual V1a/V2 blockade mediated by pecavaptan provides haemodynamic benefits in addition to aquareisis in two different large-animal models.

**Methods**

**Ethics statement**

All study procedures conformed to the current national legislation [German protection of animals act (18 May 2006), last amended by article 4 paragraph 87 (BGBl. I S. 1666) on 18 July 2016] and EU directive 63/2010 (on the protection of animals used for scientific purposes). All performed studies were approved by the competent regional regulatory authority (LANUV NRW in Duesseldorf, Germany) and by the institutional animal care office of Bayer AG.

**Cell-based assays**

Cell culture experiments describing cell lines and IC50 determination in recombinant CHO (Chinese Hamster Ovary, CHO K1; American Type Culture Collection, Manassas, VA, USA) cells stably expressing human V1a and V2 receptors are described in Kolkhof et al.10 Recombinant CHO cell lines expressing the cloned dog V1a and V2 receptors were established accordingly. In the case of the Gq-coupled canine V1a receptor, cells were also stably transfected with a modified form of the calcium-sensitive photoprotein obelin (dog V1a), which, after reconstitution with the cofactor coelenterazine, emits light when free intracellular calcium concentrations increase.11 The Gs-coupled canine V2 receptor was stably transfected into a CHO cell line expressing the gene for firefly luciferase under control of a CRE-responsive promoter. Activation of human and dog V2 receptors induces the activation of the CRE-responsive promoter via cAMP increase, thereby inducing the expression of firefly luciferase. The light emitted by photoproteins of V1a cell lines as well as the light emitted by firefly luciferase of V2 cell lines corresponds to the activation or inhibition of the respective AVP receptor. The bioluminescence of the cell lines is detected using a suitable luminometer. All cell culture and test conditions were performed as described by Kolkhof et al.10

**Canine tachypacing-induced model of heart failure**

Pecavaptan and tolvaptan were investigated in anaesthetised dogs with HF based on a previously reported protocol.12 On Day 0, six dogs were anaesthetised (initial anaesthesia: thiopental sodium 0.25–0.5 mg/kg, Trapanal®, Byk Gulden, Germany); maintenance: isoflurane (1.0–2.0%; Baxter, Germany), intubated and ventilated (Avance® anaesthesia ventilator, GE Healthcare, Germany; applying 30% oxygen) to implant a pacemaker lead (Sorox S60, Biotronik, Germany) into the right atrium. After connecting the pacemaker lead to the pacemaker (Logo®, Biotronik, Germany), intracardiac signals were measured to ensure correct lead placement. For analgesia, fentanyl (10–40 μg/kg per hour; Mallinckrodt Inc.) was infused intravenously during the implantation procedure. In the wound-healing phase, all animals were treated with parenteral antibiotic (Chloroole, Pfizer, USA; subcutaneous) and analgesic (Metamizole WDT, WDT, Germany; 50 mg/kg; intramuscular). After wound healing (Day 14), the pacemakers were activated, and the right ventricles continuously stimulated with 220 bpm for 28 days. To investigate the tachypacing-induced changes in heart function and dimensions, echocardiography (Vivid-I, GE Healthcare, Germany) investigations were performed under healthy conditions and after 28 days of pacing.

After 28 days of pacing (Day 42), animals were studied to investigate systemic and cardiac haemodynamics and urine volume responses to an intravenous (i.v.) bolus of tolvaptan (0.01, 0.03, 0.1 and 0.3 mg/kg) or pecavaptan (0.01, 0.03, 0.1 and 0.3 mg/kg). Under sterile conditions the animals were instrumented with femoral artery access to measure arterial blood pressure via a NaCl 0.9%-filled sheath introducer (Cordis®, Waterloo, Belgium), and left ventricular performance was assessed using electrocardiogram (EKG) and a SF-microtip catheter (Millar Instruments Inc., USA). Through an axillary vein, a Swan–Ganz catheter (CCOmbo® with Vigilance® monitor, Edwards Lifesciences, USA) was introduced to measure cardiac output (CO). All data were recorded and analysed with Ponemah software (Data Sciences International, USA). After completion of the instrumentation, AVP (Sigma-Aldrich, Darmstadt, Germany) was given as an i.v. infusion at a rate of 4 μl/kg/min. The animals were further randomised to receive tolvaptan (n = 3) or pecavaptan (n = 3) (Figure 7).

Pecavaptan and tolvaptan were dissolved in dimethyl sulfoxide (1%, Sigma), polyethylene glycol (49.5%, Sigma) and transcutol (49.5%, Sigma). Vehicle (only solvent) and cumulative dosages of pecavaptan or tolvaptan were administrated by i.v. bolus injection 20 min after the AVP infusion was started. Haemodynamic parameters were recorded over 20 min after i.v. bolus injection.

**Non-invasive telemetric cardiac output monitoring in conscious dogs**

A second study was performed to evaluate efficacy in the conscious state. Nine healthy beagle dogs (Marshall BioResources, USA)
Cardiac output improvement by pecavaptan

Figure 1 Study design using a canine tachypacing model of heart failure. AVP, arginine vasopressin.

Figure 2 Study design for cardiac output monitoring in conscious telemetric dogs. AVP, arginine vasopressin.

were instrumented with implantable telemetry sensors (Model L21, Data Sciences International, USA) for haemodynamic assessment. Therefore, animals were anaesthetised with thiopental sodium (0.25–0.5 mg/kg to effect; Trapanal, Byk Gulden, Germany). During implantation procedures, animals were intubated and mechanically ventilated with 30% oxygen (Avance® anaesthesia ventilator, GE Healthcare, Germany). Anaesthesia supplementation was provided by isoflurane (1.0–2.0%; Baxter, Germany) and administered via anaesthetic gas. For analgesia, fentanyl (10–40 μg/kg/h) was infused through the cephalic vein. After left-sided thoracotomy, a pressure catheter was placed in the thoracic aorta to measure blood pressure. A second pressure catheter was inserted into the apex of the left ventricle to measure left ventricular pressure. Furthermore, electrodes were placed in apical and basal positions of the heart for continuous ECG recording. The electronic housing of the device was placed submuscular on the left thorax side. For telemetric data capture and data analysis Ponemah software (Version 5.2, Data Sciences International, USA) was used.

On the day of the study, additional surface sensors (CHEETAH NICOM™, USA) were placed for non-invasive CO monitoring. The NICOM technology (Non-Invasive Cardiac Output Monitoring) has been previously validated by Heerdt et al.13 for the measurement of drug-induced changes of CO in dogs. Sensors were placed on the backs of the dogs and CO was measured continuously every 30 s. Additional bladder catheters were placed to investigate the V2-mediated (diuretic) effects by determination of urine volume within each intervention (Figure 2). One hour before the telemetric measurements started, animals were orally pre-treated [as solution in gelatine capsules (HGK 15-30, Kruger, Germany)] with vehicle (0.5 mL/kg of PEG 400, Sigma-Aldrich Chemie GmbH, Germany), pecavaptan (3 mg/kg in vehicle) or tolvaptan (10 mg/kg in vehicle). The respective doses of pecavaptan and tolvaptan were determined as matching aquaretic efficacy in previous pilot studies.

Afterwards, all dogs were treated with vehicle (physiological NaCl, B. Braun, Germany) and cumulative dosages (3, 10 and 30 ng/kg/min; 15 min of i.v. infusion per dose) of AVP (Sigma-Aldrich, Germany) to mimic elevated AVP levels in patients with HF. CO (L/min), cardiac index (CI; L/min/m²), total peripheral resistance (TPR, dyn × s/cm⁵), HR (bpm), blood pressure (mmHg) and contractility (+dP/dt, mmHg/s) were measured continuously. In this crossover-designed study, each dog was treated on individual days with placebo, tolvaptan and pecavaptan. A washout period of one week was applied between experiments.

In both studies, urine and blood parameters were measured by standard methods by a clinical-chemical analyser system (ADVIA 2400, Siemens).

Data analysis and statistical calculations
In the tachypacing-induced HF model, for each animal and intervention (control, vehicle, tolvaptan or pecavaptan) haemodynamic data were analysed and averaged between 15 and 20 min post bolus injection. TPR was calculated as the product of mean blood pressure multiplied by 80, divided by CO. The percentage difference compared with the individual baseline measurements (controls) were calculated and expressed as mean data of \( n = 3 \) animals ± standard error of the mean (SEM). Urine was collected over a period of 20 min for every animal and intervention and expressed as mean data ± SEM. The corresponding dosage groups (tolvaptan and pecavaptan) were statistically analysed. Group differences (tolvaptan vs. pecavaptan) were analysed using a Student’s unpaired \( t \)-test. An alpha-level of <0.05 was used to indicate statistical significance.

© 2020 Bayer AG. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
In conscious animals, haemodynamic data were analysed and averaged between 13 and 15 min post start of infusion for every AVP dose. In case of an inadequate online evaluation, the stored data could be evaluated offline. Data generated with signal noise, disrupted transmission or other artefacts were not considered for evaluation. TPR was calculated as described before and CI was analysed by the quotient of CO and the body surface area. Urine was collected over an individual period of 15 min, starting at the beginning of the individual interventions (control, placebo or AVP). All data were expressed as averaged absolute values of \( n = 9 \) animals ± SEM in graphics or standard deviation in text. Treatment groups were compared to corresponding individuals in the placebo group and were analysed using a repeated-measure one-way ANOVA and Tukey multiple comparison test. A \( P \)-value of <0.05 was defined as demonstrating statistical significance.

In both studies, the pre-defined study goal was a statistically significant improvement in CO and/or TPR in comparison to the reference group (placebo or tolvaptan).

Results

In vitro

IC50 determination at recombinant cell lines stably expressing the human and canine AVP receptors revealed similar individual receptor selectivity profiles for pecavaptan and tolvaptan. Table 1 shows that pecavaptan has a selectivity profile of 2.1 and 3:1 at human and dog receptors, respectively (i.e. slightly in favour of V2 receptors), based on IC50 values. In contrast, tolvaptan was found to possess a 19:1 selectivity profile at human V2:V1a receptors and has a 10:1 selectivity profile at dog V2:V1a receptors.10

In vivo

After confirmation of similar profiles at human and canine receptors, dual V1a/V2 receptor antagonism mediated by pecavaptan and selective V2 receptor antagonism mediated by tolvaptan were investigated in two pre-clinical canine models: (a) an established experimental setup in tachypacing-induced HF with application of exogenous AVP in anaesthetised dogs, and (b) oral application of pecavaptan and tolvaptan to conscious dogs with implantable and wearable devices under AVP infusion.

Tachypacing-induced heart failure in dogs

Tachypaced dogs were investigated by invasive catheter-based methods before drug treatment. Online supplementary Table S1 shows that all HF dogs developed a significant increase in filling pressure (left ventricular end-diastolic pressure), as well as a decline in contractility (+dP/dt) and relaxation (−dP/dt) compared with healthy animals. Echocardiographic investigations (Table 2) confirmed the expected changes in heart function (decrease in ejection fraction and fractional shortening) and dimensions (increase in left ventricular end-systolic and end-diastolic volume) without any significant group differences.

Intravenous bolus injection of tolvaptan and pecavaptan counteracted the diuretic activity of AVP infusion and induced dose-dependent increases in urine volume with equal efficacy on urinary output (UOP) and without any significant difference between these two treatments (Figure 3A).

Intravenous infusion of AVP led to a CO decrease of \(-14.4 \pm 0.90\) % in the tolvaptan group and \(-11.41 \pm 3.35\) % in the pecavaptan group (compared with baseline measurements; Figure 3B). Pecavaptan fully counteracted the decrease in CO, whereas tolvaptan exhibited only a slight trend of improvement in the 100 and 300 μg/kg doses. In comparison with tolvaptan, pecavaptan was significantly \((P < 0.05)\) superior in the 30 and 100 μg/kg doses in protecting from AVP-mediated CO decrease. Similarly, infusion of AVP led to an increase in TPR \(+13.9 \pm 6.2\) %, tolvaptan group; \(+11.3 \pm 2.5\) %, pecavaptan group) and cumulative dosages of pecavaptan counteracted these V1a-mediated effects in a statistically significant manner.
Cardiac output improvement by pecavaptan

Conscious telemetric dogs with cardiac output monitor

Telemetry devices were successfully implanted, and all sensors delivered accurate physiological biopotential (ECG) or pressure (blood pressure and left ventricular pressure) signals during the whole study. Non-invasive CO monitoring by bioimpedance measurement also delivered plausible results with respect to baseline data and during AVP infusion. All single experiments were in accordance with the study protocol and no dropouts were registered.

Oral pre-treatment with placebo did not lead to any changes in urinary volume in the time course of the acute study. In comparison, pre-treatment with pecavaptan as well as tolvaptan was able to significantly (P < 0.05, in comparison with placebo group) increase UOP during exogenous AVP infusion with 3 and 10 ng/kg/min, but not with 30 ng/kg/min (Figure 4A). In Figure 4B, the V1a-mediated effects of AVP after placebo, pecavaptan or tolvaptan are shown. No differences during control conditions were observed. Increasing dosages of AVP led to a dose-dependent decrease in CO (3 ng/kg/min: −14.7 ± 19.8%; 10 ng/kg/min: −33.0 ± 13.3%; 30 ng/kg/min: −36.2 ± 14.4%, compared with control measurements) in the placebo group. Tolvaptan led to a non-significant trend towards higher CO values (3 ng/kg/min: +0.09 ± 0.19 L/min; 10 ng/kg/min: +0.15 ± 0.12 L/min; 30 ng/kg/min: +0.07 ± 0.13 L/min; compared with corresponding placebo measurements). In contrast, oral pre-treatment with pecavaptan significantly counteracted the AVP-induced changes in CO (3 ng/kg/min AVP: +0.19 ± 0.26 L/min, non-significant; 10 ng/kg/min AVP: +0.32 ± 0.21 L/min, P = 0.002; 30 ng/kg/min AVP: +0.26 ± 0.17 L/min, P = 0.0086; compared with corresponding placebo measurements). In the placebo group, AVP infusion led to a dose-dependent decrease in CI (3 ng/kg/min AVP: −14.3 ± 20.3%, 10 ng/kg/min AVP: −32.5 ± 13.4%, 30 ng/kg/min AVP: −35.6 ± 13.4%; compared with control measurements), whereas pecavaptan — but not tolvaptan — could protect from a respective decline in CI (3 ng/kg/min AVP: +0.46 ± 0.64 L/min/m²; 10 ng/kg/min AVP: +0.75 ± 0.53 L/min/m²; 30 ng/kg/min AVP: +0.58 ± 0.39 L/min/m²; compared with corresponding placebo group). Similar to observations from the experimental setup in anaesthetised dogs, AVP infusion led to the expected increase in TPR in the placebo group, which peaked with 14.32 ± 4883.57 dyn x s/cm² in the 30 ng/kg/min AVP dose. Pre-treatment with pecavaptan led to a significant TPR decrease (3 ng/kg/min AVP: −2054.3 ± 2864.64 dyn x s/cm²; 10 ng/kg/min AVP: −4533.4 ± 3078.8 dyn x s/cm², P < 0.0001; 30 ng/kg/min AVP: −5348.6 ± 3601.3 dyn x s/cm², P < 0.0001; compared with corresponding placebo group), whereas tolvaptan was without a statistically significant effect here (3 ng/kg/min AVP: −1091.3 ± 1925.1 dyn x s/cm²; 10 ng/kg/min AVP: −2597.3 ± 2886.2 dyn x s/cm²; 30 ng/kg/min AVP: −2541.4 ± 2634.3 dyn x s/cm²; compared with corresponding placebo group).

There were no differences between the tolvaptan group and the pecavaptan group in plasma sodium, osmolality, potassium and creatinine, indicating that neither plasma electrolyte homeostasis nor renal function was differentially modified (online supplementary Figure S1).

(P = 0.011) vs. tolvaptan (tolvaptan: 4412.3 ± 358.8 dyn x s/cm²; pecavaptan: 3287.4 ± 247.8 dyn x s/cm²; 300 μg dose).

There were no differences between the tolvaptan group and the pecavaptan group in plasma sodium, osmolality, potassium and creatinine, indicating that neither plasma electrolyte homeostasis nor renal function was differentially modified (online supplementary Figure S1).
Figure 4  Diuretic (A) and haemodynamic (B–D) effects of oral treatment with pecavaptan or tolvaptan during infusion of increasing dosages of arginine vasopressin (AVP). All data are mean of \( n = 9 \) ± standard error of the mean. CI, cardiac index; CO, cardiac output; PI, placebo; TPR, total peripheral resistance; UV, urine volume. \( *P < 0.05; **P < 0.01; ***P < 0.001 \).
from AVP-mediated impairment in cardiac and systemic function. A statistically significant difference of the pre-defined study goal was already reached with three animals per group. With regard to the predictive value of the chosen model, one should take into consideration that anaesthesia and surgical trauma might exert major biases on physiologic and pharmacologic interventions. To investigate if the observed effects also translate into a more predictive scenario, we developed a new model, in which we tested the haemodynamic and diuretic effects of pecavaptan vs. tolvaptan in conscious animals. Here, we used implantable telemetric sensors and wearable devices to measure relevant haemodynamics non-invasively. Oral pre-treatment with pecavaptan significantly protected from AVP-induced haemodynamic impairment, whereas tolvaptan had only minor, non-significant effects on these HF-relevant parameters. Therefore, pecavaptan may serve to blunt V1a-mediated effects seen with chronically elevated AVP levels (i.e. peripheral vasoconstriction) while maintaining the favourable effects of V2 antagonism (i.e. volume depletion). Based on its combined aquaretic and haemodynamic profile, pecavaptan could be useful in acute, worsening or chronic HF, either as adjunctive therapy or as a replacement for loop diuretics. In the latter case, pecavaptan might represent an equally effective but safer mode of achieving decongestion with potential additional benefit from acute haemodynamic and chronic anti-remodelling effects mediated via V1a blockade in patients with HF. Moreover, pecavaptan might be invaluable for congested patients with late-stage chronic kidney disease given that activation of renal vascular V1a receptors decreases renal blood flow and oxygenation in settings of increased vasopressin levels, at least in pre-clinical animal models.

Limitations of these studies are a result of the acute experimental setting and an uncertainty about the relevance of controlled AVP administration to the pathophysiological mechanism of neuro-hormonally induced non-osmotic AVP release. One limitation of UOP measurement in our studies is associated with the acute experimental setup with observational periods of 15 to 20 min per dosage, although we used bladder catheters for accurate UOP measurement. A further limitation concerns the measurement of CO/CI by the NICOM technology. The NICOM device measures the bioimpedance or the phase shift in voltage across the thorax and there may be experimental situations (e.g. during periods of low flow) causing readings of decreased accuracy. Further future investigations should aim to differentiate against or on top of standard of care, as well as on potential effects on tissue remodelling in chronic studies, which was out of the scope of the current study. The currently ongoing phase II AVANTI trial (NCT03901729) is assessing the safety and efficacy of pecavaptan, with or without furosemide, vs. furosemide alone in patients admitted to hospital with acutely decompensated HF and objective evidence of incomplete decongestion despite standard HF treatment.

### Supplementary Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

### Acknowledgements

Portions of the results have been presented in the form of abstracts at the recent congresses of the European Society of Cardiology (ESC) in Rome in 2016 and ESC Heart Failure in Vienna in 2018.

### Funding

This work was supported by Bayer AG.

**Conflict of interest:** At the time of study, the following authors were employees of Bayer AG: TM, PW, CS, JH, WD, HT, PK.

### References

1. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. *Am J Med* 2006;119(12 Suppl 1):53–510.

2. Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. *Nat Rev Cardiol* 2015;12:220–229.

3. Felker GM, O’Connor CM, Braunwald E. Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? *Circ Heart Fail* 2009;2:56–62.

4. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. *J Am Coll Cardiol* 2005;46:1785–1791.

5. Schrier RW, Gross P, Gheorghiade M, Beri T, Verbicas JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatraemia. *N Engl J Med* 2006;355:2099–2012.

6. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zannino M, Orlandi C; Tolvaptan Investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. *Circulation* 2003;107:2690–2696.

7. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannino F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. *JAMA* 2007;297:1323–1343.

8. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannino F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome trial. *JAMA* 2007;297:1319–1331.

9. Vaduganathan M, Goldsmith SR, Senni M, Butler J, Gheorghiade M. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial. *Eur J Heart Fail* 2016;18:185–191.

10. Kolkhof P, Pook E, Paskovic M, Kretschmer A, Buchmüller A, Tinel H, Delbeck M, Mondzinski T, Wannaire P, Oshiwake W, Truebel H, Häser J, Schmeck C. Vascular protection and decongestion without renin-angiotensin-aldosterone system stimulation mediated by a novel dual-acting vasopressin V1a/V2 receptor antagonist. *J Cardiovasc Pharmacol* 2019;74:44–52.

11. Illarramendi BA, Bondar VS, Illarramendi VA, Vysockis ES. Sequence of the cDNA encoding the Csa(2+)–activated photoprotein obelin from the hydroid polyp *Obelia longissima*. Gene 1995;153:227–274.

12. Mondzinski T, Kolkhof P, Sabbah HN, Gheorghiade M, Furstner C, Schmeck C, Schedentop H, Schaefer S, Truebel H. Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2a/V1a receptor blockade in a preclinical heart failure model. *Am J Ther* 2011;18:31–37.

13. Heerdt PM, Wagner CL, DeMai M, Savarese JJ. Noninvasive cardiac output monitoring with bioimpedance as an alternative to invasive instrumentation for preclinical drug evaluation in beagles. *J Pharmacol Toxicol Methods* 2011;64:111–118.

14. Costanzo MR, Negoiu D, Jaski BE, Bart BA, Heywood JT, Anand IS, Smlesser JM, Kaneshige AM, Chomsky DB, Adler ED, Haas GJ, Watts JA, Nabul JI, Schollmeyer MP, Fonarow GC. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. *JACC Heart Fail* 2016;4:95–105.

15. Malhotra R, Bakken K, D’Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. *JACC Heart Fail* 2016;4:607–616.
16. Schäfer S, Kolkhof P. Failure is an option: learning from unsuccessful proof-of-concept trials. Drug Discov Today 2008;13:913–916.

17. Dixon JA, Spinale FG. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail 2009;2:262–271.

18. Elsner D, Riegger GA. Experimental heart failure produced by rapid ventricular pacing in the dog. J Card Fail 1995;1:229–247.

19. Yarbrough WM, Spinale FG. Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol 2003;10:77–86.

20. Vatner SF, Braunwald E. Cardiovascular control mechanisms in the conscious state. N Engl J Med 1975;293:970–976.

21. Goldsmith SR, Udelson JE, Gheorghiade M. Dual vasopressin V1a/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure? J Card Fail 2018;24:112–114.

22. Perico N, Zaja C, Corna D, Rottoli D, Gaspari F, Haskell L, Remuzzi G. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009;76:960–967.